Ultra Coils From Start to Finish for the Endovascular Repair of Small Intracranial Aneurysms
NCT ID: NCT02657772
Last Updated: 2022-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2013-11-30
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TARGET Intracranial Aneurysm Coiling Registry
NCT01748903
EffectiveNess and SAfety of Small ANeurysm COiling Trial
NCT02167997
Assessing the WAVE Extra Soft Coil in Intracranial Aneurysms and Comparing Imaging Modalities
NCT04106583
Hydrogel Endovascular Aneurysm Treatment Trial
NCT01407952
Study of the Penumbra Coil 400 System to Treat Aneurysm
NCT01465841
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Procedure
1. Screening and Informed consent: Patients will undergoing endovascular treatment of intracranial aneurysm will be screened using the Eligibility criteria checklist, and enrolled using approved Institutional Informed Consent process and approved Informed Consent form.
2. Baseline assessment: This involves standard of care history, medical examinations and laboratory assessments prior to coiling procedure.
3. Coiling procedure
4. One day post procedure assessment
5. 3- 28 days post procedure assessment
6. 3-9 months post procedure assessment
7. 9-18 months post procedure assessment
The Site investigator and/or co-investigator or their representative(s) will conduct training before initiating the study to develop a common understanding of the clinical protocol, Case Report Forms, and study procedures among the investigators and site research staff. Regulatory binders with study protocol, training documents, and standard operating guidelines will be provided for each study site. The Principal investigator and/or co-investigator shall confirm data received is accurate by reviewing with the provider collecting the data. The principle investigator and/or co-investigator will approve all data received. Additionally, OpenClinica, a web-based data capture service, will receive all Case Report Forms.
Study Monitoring will be electronic requiring upload of de-identified source documents through provided secure channels. However on site visits maybe scheduled in advance with the site personnel. Audits may be also be performed for quality assurance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient has a documented untreated intracranial aneurysm less than or equal to 5.0 mm in maximal dimension, ruptured or unruptured, suitable for embolization with coils.
3. Target® Ultra coils may be used.
4. Target aneurysm can be completely or nearly completely coiled at index procedure (No staged treatment procedures) without anticipated need for any target aneurysm reintervention after 72 hours of the index procedure. If a stent is to be placed during a separate preliminary procedure, then screening and enrollment for the coiling procedure must take place after the stenting procedure is completed.
5. Target aneurysm morphology allows for adequate retention of coils within the aneurysmal sac without occlusion of the parent artery, as determined by the treating physician.
6. Patient (or patient's legally authorized representative) has provided written informed consent.
7. Patient is willing and able to comply with protocol follow-up requirements.
Exclusion Criteria
2. Target aneurysm is felt by the physician operator to be mycotic or clearly dissecting in etiology.
3. Target aneurysm is \>5.0 mm maximum luminal dimension.
4. Target aneurysm has been previously treated by surgery or endovascular therapy.
5. Target aneurysm is in the physician's estimation unlikely to be successfully treated by endovascular techniques.
6. Patient presents as Hunt and Hess grade V for a ruptured aneurysm.
7. Patient has known hypersensitivity to platinum, tungsten, nickel, stainless steel or structurally related compounds found in Target® Ultra coils.
8. Patients who have had or could have a severe reaction to contrast agents that cannot be adequately pre-medicated prior to the coiling procedure.
9. Patients who are unable to complete scheduled follow up assessments at the enrolling center due to limited life expectancy (\<24 months), comorbidities or geographical considerations.
10. Patients with Moya-Moya disease, brain arteriovenous malformation(s), significant atherosclerotic stenosis, tortuousity or other conditions preventing access to the target aneurysm.
11. Target aneurysm with significant thrombosis that may increase the likelihood of recanalization at the discretion on the investigator.
12. Female patient has a positive pregnancy assessment at baseline, breastfeeding patient, or patient who plans to become pregnant within the 18 months following coiling.
13. The following comorbidities that may confound results: (a) organ failure of kidney (b) uncorrectable coagulation abnormality.
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stryker Neurovascular
INDUSTRY
University of Maryland, Baltimore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gaurav Jindal
Assistant Professor of Radiology, Neurosurgery, Neurology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gaurav Jindal, MD
Role: PRINCIPAL_INVESTIGATOR
University of Maryland, Baltimore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Christiana Care Health System
Newark, Delaware, United States
WellStar Research Institute
Marietta, Georgia, United States
University of Maryland Baltimore
Baltimore, Maryland, United States
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Geisinger medical center
Danville, Pennsylvania, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jindal G, Almardawi R, Gupta R, Colby GP, Schirmer CM, Satti SR, Pukenas B, Hui FK, Caplan J, Miller T, Cherian J, Aldrich F, Kibria G, Simard JM; ULTRA Study Investigators. Target Ultra and Nano coils in the endovascular treatment of small intracranial aneurysms (ULTRA Registry). J Neurosurg. 2022 Jun 24;138(1):233-240. doi: 10.3171/2022.5.JNS2296. Print 2023 Jan 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HP-00055046
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.